Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0.

Law I, Albert NL, Arbizu J, Boellaard R, Drzezga A, Galldiks N, la Fougère C, Langen KJ, Lopci E, Lowe V, McConathy J, Quick HH, Sattler B, Schuster DM, Tonn JC, Weller M.

Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):540-557. doi: 10.1007/s00259-018-4207-9. Epub 2018 Dec 5.

2.

EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2.

Varrone A, Asenbaum S, Vander Borght T, Booij J, Nobili F, Någren K, Darcourt J, Kapucu OL, Tatsch K, Bartenstein P, Van Laere K; European Association of Nuclear Medicine Neuroimaging Committee.

Eur J Nucl Med Mol Imaging. 2009 Dec;36(12):2103-10. doi: 10.1007/s00259-009-1264-0.

PMID:
19838705
3.

Guidelines for 18F-FDG PET and PET-CT imaging in paediatric oncology.

Stauss J, Franzius C, Pfluger T, Juergens KU, Biassoni L, Begent J, Kluge R, Amthauer H, Voelker T, Højgaard L, Barrington S, Hain S, Lynch T, Hahn K; European Association of Nuclear Medicine.

Eur J Nucl Med Mol Imaging. 2008 Aug;35(8):1581-8. doi: 10.1007/s00259-008-0826-x. Erratum in: Eur J Nucl Med Mol Imaging. 2008 Nov;35(11):2140.

PMID:
18536914
4.

FDG-PET/CT(A) imaging in large vessel vasculitis and polymyalgia rheumatica: joint procedural recommendation of the EANM, SNMMI, and the PET Interest Group (PIG), and endorsed by the ASNC.

Slart RHJA; Writing group; Reviewer group; Members of EANM Cardiovascular; Members of EANM Infection & Inflammation; Members of Committees, SNMMI Cardiovascular; Members of Council, PET Interest Group; Members of ASNC; EANM Committee Coordinator.

Eur J Nucl Med Mol Imaging. 2018 Jul;45(7):1250-1269. doi: 10.1007/s00259-018-3973-8. Epub 2018 Apr 11. Review.

5.

Imaging of amino acid transport in brain tumours: Positron emission tomography with O-(2-[18F]fluoroethyl)-L-tyrosine (FET).

Langen KJ, Stoffels G, Filss C, Heinzel A, Stegmayr C, Lohmann P, Willuweit A, Neumaier B, Mottaghy FM, Galldiks N.

Methods. 2017 Nov 1;130:124-134. doi: 10.1016/j.ymeth.2017.05.019. Epub 2017 May 24. Review.

PMID:
28552264
6.

Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas.

Albert NL, Weller M, Suchorska B, Galldiks N, Soffietti R, Kim MM, la Fougère C, Pope W, Law I, Arbizu J, Chamberlain MC, Vogelbaum M, Ellingson BM, Tonn JC.

Neuro Oncol. 2016 Sep;18(9):1199-208. doi: 10.1093/neuonc/now058. Epub 2016 Apr 21. Review.

7.

The SNMMI and EANM practice guideline for renal scintigraphy in adults.

Blaufox MD, De Palma D, Taylor A, Szabo Z, Prigent A, Samal M, Li Y, Santos A, Testanera G, Tulchinsky M.

Eur J Nucl Med Mol Imaging. 2018 Nov;45(12):2218-2228. doi: 10.1007/s00259-018-4129-6. Epub 2018 Aug 30.

PMID:
30167801
8.

EANM procedure guidelines for brain neurotransmission SPECT/PET using dopamine D2 receptor ligands, version 2.

Van Laere K, Varrone A, Booij J, Vander Borght T, Nobili F, Kapucu OL, Walker Z, Någren K, Tatsch K, Darcourt J.

Eur J Nucl Med Mol Imaging. 2010 Feb;37(2):434-42. doi: 10.1007/s00259-009-1265-z.

PMID:
19838704
9.

EANM procedure guideline for brain perfusion SPECT using 99mTc-labelled radiopharmaceuticals, version 2.

Kapucu OL, Nobili F, Varrone A, Booij J, Vander Borght T, Någren K, Darcourt J, Tatsch K, Van Laere KJ.

Eur J Nucl Med Mol Imaging. 2009 Dec;36(12):2093-102. doi: 10.1007/s00259-009-1266-y.

PMID:
19838703
10.

EANM procedure guidelines for brain neurotransmission SPECT using (123)I-labelled dopamine transporter ligands, version 2.

Darcourt J, Booij J, Tatsch K, Varrone A, Vander Borght T, Kapucu OL, Någren K, Nobili F, Walker Z, Van Laere K.

Eur J Nucl Med Mol Imaging. 2010 Feb;37(2):443-50. doi: 10.1007/s00259-009-1267-x.

PMID:
19838702
11.

Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-L-tyrosine PET in comparison to MRI.

Galldiks N, Rapp M, Stoffels G, Fink GR, Shah NJ, Coenen HH, Sabel M, Langen KJ.

Eur J Nucl Med Mol Imaging. 2013 Jan;40(1):22-33. doi: 10.1007/s00259-012-2251-4. Epub 2012 Sep 29.

PMID:
23053325
12.

Abass Alavi: A giant in Nuclear Medicine turns 80 and is still going strong!

Høilund-Carlsen PF.

Hell J Nucl Med. 2018 Jan-Apr;21(1):85-87. doi: 10.1967/s002449910713. Epub 2018 Mar 20.

13.

[Procedure guidelines for whole-body 18F-FDG PET and PET/CT in children with malignant diseases].

Franzius C, Stauss J, Pfluger T, Juergens KU, Kluge R, Amthauer H, Juergens H, Henze G, Stoever B, Hahn K.

Nuklearmedizin. 2010;49(6):225-33; quiz N60-1. doi: 10.3413/nukmed-0322. Epub 2010 Jul 9. German.

PMID:
20617279
14.

18F-FDOPA PET/CT for detection of recurrence in patients with glioma: prospective comparison with 18F-FDG PET/CT.

Karunanithi S, Sharma P, Kumar A, Khangembam BC, Bandopadhyaya GP, Kumar R, Gupta DK, Malhotra A, Bal C.

Eur J Nucl Med Mol Imaging. 2013 Jul;40(7):1025-35. doi: 10.1007/s00259-013-2384-0. Epub 2013 Mar 23.

PMID:
23525498
15.

Increasing feasibility and utility of (18)F-FDOPA PET for the management of glioma.

Bell C, Dowson N, Puttick S, Gal Y, Thomas P, Fay M, Smith J, Rose S.

Nucl Med Biol. 2015 Oct;42(10):788-95. doi: 10.1016/j.nucmedbio.2015.06.001. Epub 2015 Jun 9. Review.

PMID:
26162582
16.

FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0.

Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, Verzijlbergen FJ, Barrington SF, Pike LC, Weber WA, Stroobants S, Delbeke D, Donohoe KJ, Holbrook S, Graham MM, Testanera G, Hoekstra OS, Zijlstra J, Visser E, Hoekstra CJ, Pruim J, Willemsen A, Arends B, Kotzerke J, Bockisch A, Beyer T, Chiti A, Krause BJ; European Association of Nuclear Medicine (EANM).

Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):328-54. doi: 10.1007/s00259-014-2961-x. Epub 2014 Dec 2.

17.

FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0.

Boellaard R, O'Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, Oyen WJ, Kotzerke J, Hoekstra OS, Pruim J, Marsden PK, Tatsch K, Hoekstra CJ, Visser EP, Arends B, Verzijlbergen FJ, Zijlstra JM, Comans EF, Lammertsma AA, Paans AM, Willemsen AT, Beyer T, Bockisch A, Schaefer-Prokop C, Delbeke D, Baum RP, Chiti A, Krause BJ.

Eur J Nucl Med Mol Imaging. 2010 Jan;37(1):181-200. doi: 10.1007/s00259-009-1297-4.

18.

The diagnostic accuracy of detecting malignant transformation of low-grade glioma using O-(2-[18F]fluoroethyl)-l-tyrosine positron emission tomography: a retrospective study.

Bashir A, Brennum J, Broholm H, Law I.

J Neurosurg. 2018 Apr 1:1-14. doi: 10.3171/2017.8.JNS171577. [Epub ahead of print]

PMID:
29624154
19.

O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma.

Hutterer M, Nowosielski M, Putzer D, Waitz D, Tinkhauser G, Kostron H, Muigg A, Virgolini IJ, Staffen W, Trinka E, Gotwald T, Jacobs AH, Stockhammer G.

J Nucl Med. 2011 Jun;52(6):856-64. doi: 10.2967/jnumed.110.086645.

20.

68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0.

Fendler WP, Eiber M, Beheshti M, Bomanji J, Ceci F, Cho S, Giesel F, Haberkorn U, Hope TA, Kopka K, Krause BJ, Mottaghy FM, Schöder H, Sunderland J, Wan S, Wester HJ, Fanti S, Herrmann K.

Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):1014-1024. doi: 10.1007/s00259-017-3670-z.

PMID:
28283702

Supplemental Content

Support Center